AB Science delays 2023 annual financial report publication
Biotechnology firm AB Science announced a slight delay in the publication of its 2023 annual financial report due to scheduling changes. The report is now expected by April 29.
Biotechnology company AB Science announced on April 10, 2024, that it will slightly delay the publication of its 2023 annual financial report. The company cited a reorganization of its board meeting schedule as the reason for the postponement.
The report, originally slated for release on April 15, is now expected by April 29. This document will provide a comprehensive overview of AB Science's financial performance and operational activities throughout the 2023 fiscal year.
AB Science is a pharmaceutical company focused on the development of innovative treatments for diseases with high unmet medical needs, including neurological diseases, inflammatory diseases, and certain cancers. Its lead compound, masitinib, is under investigation for various indications.
The company is listed on the Euronext Paris stock exchange. The delay in financial reporting is a procedural adjustment and does not impact the company's ongoing research and development activities or its commitment to regulatory compliance.